RAFFA WEALTH MANAGEMENT, LLC’s Akebia Therapeutics AKBA Stock Holding History

RAFFA WEALTH MANAGEMENT, LLC’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-64	Closed	-$920	–	281
2017 Q2	$920	Hold	64	–	–	﹤0.01%	360
2017 Q1	$589	Hold	64	–	–	﹤0.01%	366
2016 Q4	$666	Buy	64 +1	+2%	+$9	﹤0.01%	610
2016 Q3	$570	Hold	63	–	–	﹤0.01%	666
2016 Q2	$471	Hold	63	–	–	﹤0.01%	713
2016 Q1	$568	Hold	63	–	–	﹤0.01%	637
2015 Q4	$814	Buy	+63	New	+$643	﹤0.01%	462

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

RAFFA WEALTH MANAGEMENT, LLC's AKBA Position: Q3 2017 in Review

RAFFA WEALTH MANAGEMENT, LLC sold out of Akebia Therapeutics (AKBA) in Q3 2017, closing a stake of 64 shares — an estimated $920 sold.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in AKBA in Q4 2015 and held it in 7 quarters. The position peaked at $920 in Q2 2017. 119 funds tracked by Wall St. Rank hold AKBA as of Q3 2017.

RAFFA WEALTH MANAGEMENT, LLC reported no remaining Akebia Therapeutics position as of Q3 2017 after selling out during the quarter.
RAFFA WEALTH MANAGEMENT, LLC sold 64 Akebia Therapeutics shares in Q3 2017, an estimated $920.
RAFFA WEALTH MANAGEMENT, LLC first reported a position in Akebia Therapeutics in Q4 2015 and held it in 7 quarters.
RAFFA WEALTH MANAGEMENT, LLC's Akebia Therapeutics position peaked at $920 in Q2 2017.
119 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2017.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q3 2017, filed 27 Jul 2026.